Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
488
mi
from 43215
Jamaica, NY
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
488
mi
from 43215
Jamaica, NY
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
477
mi
from 43215
New York, NY
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
473
mi
from 43215
Staten Island, NY
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
473
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
349
mi
from 43215
Charlotte, NC
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
130
mi
from 43215
Beachwood, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
130
mi
from 43215
Beachwood, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
99
mi
from 43215
Cincinnati, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
99
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
99
mi
from 43215
Cincinnati, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
99
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes' Investigational Study Site
81
mi
from 43215
Mason, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes' Investigational Study Site
81
mi
from 43215
Mason, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
115
mi
from 43215
Middleburg Heights, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
115
mi
from 43215
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
2026
mi
from 43215
Portland, OR
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
2047
mi
from 43215
Salem, OR
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
2047
mi
from 43215
Salem, OR
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Study Site
416
mi
from 43215
Philadelphia, PA
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Study Site
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Study Site
525
mi
from 43215
Charleston, SC
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Study Site
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
503
mi
from 43215
Memphis, TN
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
503
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
905
mi
from 43215
Dallas, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
905
mi
from 43215
Dallas, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
992
mi
from 43215
Houston, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
992
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
1090
mi
from 43215
Sugarland, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
1090
mi
from 43215
Sugarland, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
2000
mi
from 43215
Bellevue, WA
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
2000
mi
from 43215
Bellevue, WA
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
341
mi
from 43215
Waukesha, WI
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
341
mi
from 43215
Waukesha, WI
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from 43215
Bourgas,
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from 43215
Bourgas,
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
Washington DC VA Medical Center, Washington, DC
328
mi
from 43215
Washington,
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
Washington DC VA Medical Center, Washington, DC
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
VA Maryland Health Care System, Baltimore
343
mi
from 43215
Baltimore, MD
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
VA Maryland Health Care System, Baltimore
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD
370
mi
from 43215
Perry Point, MD
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD
370
mi
from 43215
Perry Point, MD
Click here to add this to my saved trials
Duloxetine for the Treatment of Postpartum Depression
Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder
Status: Enrolling
Updated:  2/9/2016
Perinatal & Postpartum Research Program 142 Temple ST Suite 301
537
mi
from 43215
New Haven, CT
Duloxetine for the Treatment of Postpartum Depression
Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder
Status: Enrolling
Updated: 2/9/2016
Perinatal & Postpartum Research Program 142 Temple ST Suite 301
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US009
678
mi
from 43215
Jacksonville, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US009
678
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US015
1639
mi
from 43215
Tucson, AZ
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US015
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US019
1970
mi
from 43215
Glendale, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US019
1970
mi
from 43215
Glendale, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US016
2098
mi
from 43215
Oakland, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US016
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US014
1951
mi
from 43215
San Diego, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US014
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US011
1162
mi
from 43215
Denver, CO
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US011
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US018
980
mi
from 43215
Hallandale Beach, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US018
980
mi
from 43215
Hallandale Beach, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US005
795
mi
from 43215
Orlando, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US005
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US006
315
mi
from 43215
Gaithersburg, MD
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US006
315
mi
from 43215
Gaithersburg, MD
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US012
647
mi
from 43215
Weymouth, MA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US012
647
mi
from 43215
Weymouth, MA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US003
487
mi
from 43215
Jamaica, NY
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US003
487
mi
from 43215
Jamaica, NY
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US001
63
mi
from 43215
Dayton, OH
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US001
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US007
2026
mi
from 43215
Portland, OR
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US007
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US004
508
mi
from 43215
Memphis, TN
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US004
508
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US002
2006
mi
from 43215
Seattle, WA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US002
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
University of Kansas
784
mi
from 43215
Wichita, KA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
University of Kansas
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
428
mi
from 43215
Marlton, NJ
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
428
mi
from 43215
Marlton, NJ
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Global Medical Institutes, Llc
442
mi
from 43215
Princeton, NJ
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Global Medical Institutes, Llc
442
mi
from 43215
Princeton, NJ
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Michael R Liebowitz MD
480
mi
from 43215
New York, NY
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Michael R Liebowitz MD
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
412
mi
from 43215
Phildadelphia, PA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
412
mi
from 43215
Phildadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
1512
mi
from 43215
Salt Lake City, UT
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
1512
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
University of Alabama Office of Psychiatric Clinical Research
491
mi
from 43215
Birmingham, AL
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
University of Alabama Office of Psychiatric Clinical Research
491
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmacology Research Institute
1983
mi
from 43215
Encino, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmacology Research Institute
1983
mi
from 43215
Encino, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmacology Research Institute
1969
mi
from 43215
Los Alamitos, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmacology Research Institute
1969
mi
from 43215
Los Alamitos, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pacific Institute for Medical Research Inc
1982
mi
from 43215
Los Angeles, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pacific Institute for Medical Research Inc
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials